p57 Monoclonal Antibody

This gene is imprinted, with preferential expression of the maternal allele. The encoded protein is a tight-binding, strong inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation. Mutations in this gene are implicated in sporadic cancers and Beckwith-Wiedemann syndorome, suggesting that this gene is a tumor suppressor candidate. Three transcript variants encoding two different isoforms have been found for this gene.

The P57 Monoclonal Antibody is a highly specialized product that has been developed to target specific proteins within the human body. This antibody is designed to bind to the P57 protein, which is known to play a critical role in regulating cell growth and division. By targeting this protein, the P57 Monoclonal Antibody can help to inhibit the growth and proliferation of cancer cells, making it an important tool in the fight against cancer.

This product has been extensively tested and validated in a variety of laboratory settings, and has been shown to be highly effective in blocking the activity of the P57 protein. It is produced using state-of-the-art techniques and is of the highest quality, ensuring that it is both safe and effective for use in a clinical setting.

The P57 Monoclonal Antibody is available in a range of formats, including purified antibody, conjugated antibody, and recombinant antibody. This allows researchers and clinicians to choose the format that best suits their needs, and to tailor their experiments or treatments accordingly.

Overall, the P57 Monoclonal Antibody is a powerful tool for researchers and clinicians alike, and has the potential to make a significant impact in the fight against cancer. Its high specificity and effectiveness make it an invaluable resource for those working in the field of oncology, and it is sure to play an important role in the development of new cancer treatments in the years to come.